Asian macaques infected with simian immunodeficiency viruses (SIVs) isolated from African non-human primates develop a disease similar to human AIDS. SIV enters its target cells by binding to CD4 and a coreceptor, typically CCR5. Maraviroc is an entry inhibitor of human immunodeficiency virus type 1 (HIV-1) that prevents the interaction between CCR5 and the surface subunit gp120 of the viral envelope glycoprotein (Env). Thus far, the activity of maraviroc on SIV entry has been poorly studied. Here, we determined in vitro pharmacological parameters of the effect of maraviroc on the SIV Env association with CCR5. Cell-to-cell fusion inhibition assays were used to compare the susceptibility to maraviroc of the SIVsmmPBj Env-CCR5 interaction with that of HIV-1BaL Env. Analysis of dose–response curves and determination of IC₅₀ values demonstrate that increasing concentrations of maraviroc inhibit the membrane fusion activity of SIVsmmPBj Env in a manner and to an extent similar to that of HIV-1BaL Env.

感染了从非洲非人类灵长类动物中分离出来的猿猴免疫缺陷病毒 (SIV) 的亚洲猕猴会患上类似于人类艾滋病的疾病。SIV 通过与 CD4 和辅助受体（通常为 CCR5）结合进入其靶细胞。Maraviroc 是 1 型人类免疫缺陷病毒 (HIV-1) 的进入抑制剂，可防止 CCR5 与病毒包膜糖蛋白 (Env) 的表面亚基 gp120 之间的相互作用。迄今为止，maraviroc 对 SIV 进入的活性研究甚少。在这里，我们确定了马拉韦罗对 SIV Env 与 CCR5 关联的影响的体外药理学参数。细胞间融合抑制试验用于比较 SIVsmmPBj Env-CCR5 相互作用对马拉韦罗的敏感性与 HIV-1BaL Env 的相互作用。剂量反应曲线分析和 IC ₅₀测定 值表明，增加浓度的马拉韦罗以与 HIV-1BaL Env 相似的方式和程度抑制 SIVsmmPBj Env 的膜融合活性。